Cogentix Medical, Inc. (NASDAQ:CGNT)

CAPS Rating: No stars

The Company designs, develops, manufactures and markets products for endoscopy- the science of using an instrument, known as an endoscope- to provide minimally invasive access to areas not readily visible to the human eye.

CGNT News and Commentary

Caps

How do you think CGNT will perform against the market?

Add Stock to CAPS Watchlist

All Players

99 Outperform
12 Underperform
 

All-Star Players

6 Outperform
7 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top CGNT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

majakblue (< 20)
Submitted February 12, 2008

Vision Sciences has just received FDA permission to market a new line of products. The company produces endoscopic instruments and has what appears to be excellent IP. The instruments are essentially teeny video cameras on very thin wires that are… More

jed71 (99.82)
Submitted November 10, 2015

After years of investing in real life and pitching on Caps, I’m very sorry, but this is the EXACT kind of company that I have absolutely no faith in. It didn’t take me long to come to this conclusion but I do encourage you to read their SEC filings… More

CGNT VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about CGNT.

Recs

0
Member Avatar adamicius (< 20) Submitted: 2/26/2017 12:58:00 PM : Outperform Start Price: $2.18 CGNT Score: +20.52

Having prostate or other urological problem sucks, but as our lives get longer, more people will have to deal with this. Cogentix manufactures and sells urology products to treat exactly such conditions. As of late 2016, the company eliminated most of ts debt. I say: outperform.

Recs

3
Member Avatar jed71 (99.82) Submitted: 11/10/2015 1:31:31 PM : Underperform Start Price: $1.65 CGNT Score: -47.77

After years of investing in real life and pitching on Caps, I’m very sorry, but this is the EXACT kind of company that I have absolutely no faith in. It didn’t take me long to come to this conclusion but I do encourage you to read their SEC filings on your own. I didn’t have to get very deep in their 10-Q before finding this:

“The Company is the result of the Merger effective as of March 31, 2015 (the "effective date") of two medical device companies, Uroplasty, Inc. and Vision-Sciences, Inc. On the effective date of the Merger, the two companies completed an all-stock merger, pursuant to which UPI merged with and into Merger Sub. Merger Sub was the surviving company from the Merger, and changed its name to Uroplasty, LLC. After the merger, VSCI and its consolidated subsidiaries, including Uroplasty LLC, and its subsidiaries, operate under the name Cogentix Medical, Inc.

Upon closing of the Merger, the former UPI stockholders owned approximately 62.5% and the VSCI shareholders retained approximately 37.5% of the company. Accordingly, while VSCI was the legal acquirer and issued its shares in the Merger, UPI is the acquiring company in the Merger for accounting purposes and the Merger has been accounted for as a reverse acquisition under the acquisition method of accounting for business combinations. As a result, the financial statements of the Company prior to the effective date of the Merger are the historical financial statements of UPI, whereas the financial statements of the Company after the effective date of the Merger reflect the results of the operations of UPI and VSCI on a combined basis. See additional disclosure provided in note 2. We have prepared our Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, have been condensed or omitted, pursuant to such rules and regulations, although we believe that our disclosures are adequate to make the information not misleading. The consolidated results of operations for any interim period are not necessarily indicative of results for a full fiscal year. These Condensed Consolidated Financial Statements, presented herein, should be read in conjunction with the audited consolidated financial statements and related notes included in our annual report on Form 10-K for the fiscal year ended March 31, 2015.”

There is some funky stuff in the financials as well, but I didn’t feel it necessary to investigate what they were doing. So reverse merger, previous businesses, never profitable, burning cash like crazy, lots of stock issuance. This one is quite easy, in my opinion.

Recs

0
Member Avatar dbajack2 (87.69) Submitted: 1/21/2014 2:39:00 PM : Outperform Start Price: $1.40 CGNT Score: +63.04

They've got something needed and priced at good value.

Leaderboard

Find the members with the highest scoring picks in CGNT.

Score Leader

CDrews2002

CDrews2002 (32.11) Score: +210.70

The Score Leader is the player with the highest score across all their picks in CGNT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
CDrews2002 32.11 10/28/2008 Underperform NS $2.83 +3.53% +213.55% +210.02 0 Comment
DavisFreeberg 94.84 5/7/2008 Underperform NS $5.83 -49.74% +96.04% +145.79 0 Comment
rrrobz 54.64 5/14/2008 Underperform 3M $5.67 -48.33% +97.39% +145.71 0 Comment
lovenlaughs < 20 3/24/2008 Underperform 1Y $3.40 -13.83% +108.77% +122.59 0 Comment
ronaldm912000 < 20 8/10/2011 Underperform 1Y $2.40 +21.61% +134.86% +113.25 0 Comment
KimLanners < 20 4/13/2011 Underperform 5Y $2.34 +24.73% +104.54% +79.82 1 Comment
dbajack2 87.69 1/21/2014 Outperform 5Y $1.40 +108.71% +45.67% +63.04 1 Comment
Chptr152 < 20 3/13/2014 Outperform 5Y $1.55 +88.30% +42.81% +45.48 0 Comment
adamicius < 20 2/27/2017 Outperform 5Y $2.18 +33.88% +13.36% +20.52 1 Comment
Vladimir1977 < 20 5/29/2012 Outperform 3M $1.32 +121.11% +101.46% +19.65 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackRothCapital 69.87 11/5/2015 Outperform NS $1.60 +82.41% +27.48% +54.93 0 Comment

Featured Broker Partners